CRISPR

Using CRISPR to modify certain immune cells could make cancer-fighting immunotherapy more potent for a broader set of patients. Two people who went through the treatment share their stories.

In a first, doctors injected the gene-editing tool CRISPR directly into cells in patients' eyes. The experiment helped these vision-impaired patients see shapes and colors again.

Scientists successfully treated a rare disease with the experimental gene-editing technique. It could open the door to new ways of treating more common disorders in the future.

The Code Breaker profiles Jennifer Doudna, a Nobel Prize-winning biochemist key to the development of CRISPR, and examines the technology's exciting possibilities and need for oversight.

The gene-editing technology is at the center of an ethical debate. Isaacson examines it through the life of Jennifer Doudna, co-recipient of the 2020 Nobel Prize in chemistry for CRISPR's discovery.

As the first patient to receive an experimental treatment that relied on the gene-editing technique CRISPR continues to do well 17 months later, more patients seem to be benefiting, too.

Two scientists at the McGovern Institute for Brain Research at MIT say the newly developed test is so simple it could conceivably be done in someone's kitchen.

Researchers are racing to develop quick, home-based tests for the virus that could deliver test results in minutes. None do that yet, but several under development hold promise, scientists say.

Doctors used CRISPR to edit genes of cells inside a patient's eye, hoping to restore vision to a person blinded by a rare genetic disorder. A similar strategy might work for some brain diseases.

Researchers safely used CRISPR gene-editing techniques in a patient with HIV. The research provides evidence the approach may be promising for treating HIV infection.